Evaluating the Effectivenes of Antiseptic Solution Decasan in Treatment of Necrotic Soft Tisue Diseases.
Sepsis is a severe generalised infection caused usually by pathogenic bacteria. It is often the cause of hospitalization and death in patients treated in intensive care and other hospital wards. Latest research brought to better understanding of patomechanisms, took place significant development of therapy heading to improvement of general patients condition treated as a basis and additionally supported by local therapy. The aim of the study was to evaluate the possibility of using the solution Decasan in the comprehensive treatment of patients necrosis of soft tissues.


METHODS
The study included 192 patients (W/M 103/89; average -aged 53.35 ± 5.36 years). According to the classification of septic states (Chicago, 1991), patients were divided into three groups: first - patients to the local form of the infection, the second - with Systemic Inflammatory Response Syndrome (SIRS), which lasted up to 72 hours and the third - patients with various forms of sepsis, SIRS in which lasted 72 hours.


RESULTS
As a result of our studies carried out in patients where the wound was made decontamination solution Decasanu, received: pain reduction, decrease tissue swelling, early debridement of the wound and the appearance in the wound granulation, to reduce delays wound healing. Proposed algorithms treatment of various forms of sepsis, pointed out the essential elements, ie.: a comprehensive approach to the treatment of infection by early surgical intervention, intensive supportive therapy (fluid resuscitation), antibiotic therapy directed to microorganisms that cause infections and topical antiseptics therapy (solution Decasanu).


CONCLUSIONS
The preparation antiseptic Decasan can be safely used for disinfection of skin, mucous membranes and wounds in the foci of infections caused by bacteria, fungi and protozoa.
Julia
J
Fuss
Victor
V
Palii
Anna
A
Voloboyeva
D000287:Administration, Topical; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use*; D003646:Debridement; D003650:Decamethonium Compounds / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018805:Sepsis / Q000188:drug therapy*; D014945:Wound Healing; D014946:Wound Infection / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D003650:Decamethonium Compounds; C000858:decamethoxine